Skip Navigation


Human Molecular Genetics Advance Access originally published online on January 13, 2004
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/5/543    most recent
ddh053v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Beilina, A.
Right arrow Articles by Hagerman, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beilina, A.
Right arrow Articles by Hagerman, P. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2004, Vol. 13, No. 5 543-549
DOI: 10.1093/hmg/ddh053

Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element

Alexandra Beilina1, Flora Tassone1, Philip H. Schwartz2, Parminder Sahota1 and Paul J. Hagerman1,*

1Department of Biological Chemistry, University of California, Davis, School of Medicine, Davis, CA, USA and 2Children's Hospital of Orange County Research Institute, Orange, CA, USA

Received November 5, 2003; Accepted December 26, 2003


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Fragile X syndrome, the most common form of mental impairment, is caused by expansion of a (CGG)n trinucleotide repeat element located in the 5' untranslated region of the fragile X mental retardation 1 (FMR1) gene. Repeat expansion is known to influence both transcription and translation; however, the mechanisms by which the CGG element exerts its effects are not known. In the current work, we have utilized 5'-RLM-RACE to examine the influence of CGG repeat number on the utilization of transcription start sites in normal (n<55) and premutation (54<n<200) cell lines of both non-neural (lymphoblastoid) and neural (primary astrocyte) origin. Our results demonstrate that, in both neural and non-neural cells, transcription of the FMR1 gene is initiated from several transcription start sites within a ~50 nt region that lies ~130 nt upstream of the CGG repeat element. For normal alleles, most transcripts initiate from the downstream-most start site, close to the single position identified previously. Surprisingly, as the size of the CGG repeat expands into the premutation range, initiation shifts to the upstream sites, suggesting that the CGG element may act as a downstream enhancer/modulator of transcription. The shift in start site selection for both neural and non-neural cells indicates that the effect is general. Furthermore, the correspondence between start site utilization and the degree of elevation of FMR1 mRNA suggests that a substantial fraction of the increased message in the premutation range may derive from the upstream start sites.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Fragile X syndrome, the most common inherited form of mental impairment, is a trinucleotide repeat expansion disorder in which expansion beyond 200 repeats (full mutation) of a (CGG)n element in the 5' untranslated (UTR) region of the fragile X mental retardation 1 (FMR1) gene generally leads to transcriptional silencing (1,2). Reduced levels, or absence of FMR1 protein (FMRP), lead to fragile X syndrome (1,3,4).

The FMR1 promoter region possesses a CpG-rich island, but lacks a canonical TATA box (5). Previously, primer extension studies have identified a transcription initiation site 134 bp upstream of the CGG repeat (6), which is generally regarded as being the predominant if not the only point of initiation of FMR1 transcript synthesis. However, no studies have further characterized the promoter region of the FMR1 gene for the presence of additional transcription start sites, nor has there been any determination as to whether the initiation site may be altered for expanded alleles.

Two major consensus sites, USF1/USF2 and alpha-Pal/Nrf-1, within the FMR1 promoter have been shown to be involved in positive regulation of FMR1 expression (7). A mutation in either one of these regions results in a more than 5-fold reduction in promoter activity, whereas mutation of both of these regions completely abolishes promoter activity (5,7,8); mutations within a TATA-like element had essentially no effect on transcriptional activity. Thus, USF1/2 and alpha-Pal/Nrf 1 appear to be important, positive cis elements for FMR1 alpha-Pal/Nrf1 expression.

For CGG repeat expansions in the premutation range (55–200 CGG repeats), FMR1 mRNA levels are elevated by as much as 5-fold in the upper premutation range (>100 CGG repeats) (911). The basis for the increased FMR1 mRNA levels is not known at present, although the higher levels do not appear to be due to increased mRNA stability (10). Moreover, in spite of the increased levels of FMR1 mRNA, FMRP levels are slightly to moderately reduced in the premutation range (9,11). A translational deficit directly correlating with CGG repeat number has been reported for premutation alleles (12). These findings suggest that the expanded CGG repeat is capable of influencing both transcription and translation of the FMR1 gene. However, all of these investigations have implicitly assumed that there is a single site for the initiation of transcription, and that this site remains unchanged for expanded alleles.

To address the question of number and position(s) of sites of transcriptional initiation, we examined transcription initiation start sites in normal and premutation lymphoblastoid cell lines, and in primary astrocyte culture derived from post-mortem tissue, using RNA ligase-mediated rapid amplification of the 5' cDNA end (RLM-RACE). Our analysis reveals that transcription of the FMR1 gene is initiated from several start sites, and that start site selection—in both neural and non-neural cells—is modulated by the number of CGG repeats in the downstream (CGG)n element.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Transcription of the FMR1 gene is initiated at multiple sites
The transcription start sites of the human FMR1 gene were determined using 5' RNA ligase-mediated rapid amplification (RLM-RACE) analysis, which has proven to be a very sensitive and accurate method to obtain full-length 5' ends of cDNAs, and to ensure that truncated messages are eliminated from the amplification reactions (13,14). 5'-RLM-RACE analysis was used to determine the transcription start sites in a lymphoblastoid cell line with a normal number of CGG repeats (female, AG; 21, 29 CGG repeats). Sequencing of 27 clones for the normal cell line has identified the presence of three distinct clusters (sites) for initiation of FMR1 transcripts, starting at the positions within –132 to –128, –166 to –162, and –181 to –177 (where +1 for the translation start site with a reference CGG repeat number of 16; Fig. 1); these clusters are designated sites I–III, respectively. Site I is close to the previously reported transcription start site determined by primer extension analysis (–135; Fig. 1) (6). Our results indicate that site I is the major transcription start site, represented in 67% of total clones (Fig. 2). The other two sites (sites II and III) are represented in 15% and 18% of the clones, respectively, and are located ~40 and 50 bp upstream of the major transcription start site (site I).



View larger version (32K):
[in this window]
[in a new window]
 
Figure 1. Region of the FMR1 gene including the CGG element (16 CGG repeats), CpG island, transcription factor binding sites, and translation start sites. Nucleotide positions are numbered to the right with respect to the start of translation at +1 (ATG). The multiple transcription start sites deduced from the current 5'RLM-RACE experiments are noted by the solid triangles, and are designated as site I, site II and site III. The asterisk marks the previously identified transcription start site (6). Transcription factor binding sites are indicated by boxes. Initiator-like (Inr-like) sequences are underlined. FMR1-specific primer positions are designated by arrows.

 


View larger version (22K):
[in this window]
[in a new window]
 
Figure 2. Distribution of transcription start sites for normal (21 or 29 CGG), and premutation (60, 82 or 160 CGG repeats) lymphoblastoid cell lines; 100% is the total number of sequenced clones for each lymphoblastoid cell line. Site I (black); site II (light gray); site III (dark gray).

 
The length of the downstream CGG repeat element influences the distribution of transcription start sites
Premutation alleles are known to be associated with elevated levels of FMR1 mRNA (911). However, it is generally assumed that the increased mRNA levels with increasing CGG repeat are simply quantitative; that is, that the same mRNA species is/are being produced, independent of CGG repeat length. To examine this issue in more detail, we determined the relative utilization of each of the three transcription start sites, for three lymphoblastoid cell lines harboring premutation alleles (60, 82, 160 CGG repeats; Table 1), using 5'-RLM-RACE. As for the normal allele, transcription initiated at all three sites; however, the fraction of initiation events from each site differed significantly between normal and premutation alleles (Fig. 2; Table 2).


View this table:
[in this window]
[in a new window]
 
Table 1. Summary of cell lines used in 5'-RLM-RACE experiments
 

View this table:
[in this window]
[in a new window]
 
Table 2. {chi}2 and P-values for differences in start site utilization for various pairs of alleles
 
We sequenced 27 clones for the 21/29 CGG repeat alleles, 32 clones for the 60 CGG repeat allele, 33 clones for the 82 CGG repeat allele and 47 clones for the 160 CGG repeat allele (Table 1). Site I was the major transcription start site for the normal cell line and was represented in 67% of the clones (Fig. 2). In contrast, site III was the major transcription start site for the two largest premutation cell lines (82 and 160 repeats), represented in 55 and 58% of clones, respectively. For the low premutation allele (60 repeats), mRNA generated from site II was the major species, represented in 50% of the clones. As demonstrated by the {chi}2 statistics presented in Table 2, start site utilization undergoes a significant shift to upstream start sites as the CGG repeat expands from normal to the low premutation range (normal to 60; P=0.017), and from the low premutation to mid/high premutation range (60 to 82, 60 to 160; P=0.0001). These results indicate that start site selection for transcription of the FMR1 gene is influenced by the downstream CGG element.

Transcripts initiated from upstream start sites (sites II and III) are proportionally represented within the pool of polyadenylated mRNA
We have investigated the possibility that the RNA species produced from the upstream sites are the products of abortive initiation. This possibility is underscored by the observation that abortive transcripts ~200 nt in length are produced from upstream sites during HIV virus transcription (15). To address this issue, we repeated the 5'-RLM-RACE experiments with polyA(+) mRNA isolated from lymphoblastoid lines that possess either normal (21 or 29 CGG repeats) or premutation (82 CGG repeats) alleles. PolyA(+) RNA representing all three start sites was found for both lines, and in approximately the same proportions to the fractions initiating at each site in the total RNA pools. For sites I–III, the polyA(+) RNAs yielded 16, 5 and 3 clones, respectively, for the normal line [total versus polyA(+) RNA; P=0.88]; and 3, 6, and 14 clones, respectively, for the 82 CGG allele [total versus polyA(+) RNA; P=0.86]. Thus, transcripts initiated from all three sites are processed into polyA(+) message.

The CGG element also influences start site selection in human primary astrocytes
To determine whether the distribution of start sites, and their utilization, is similar in neural cells, we performed 5'-RLM-RACE experiments with primary astrocytes derived from both normal (15 CGG) and premutation (87 CGG) alleles (16). In accord with the results from lymphoblastoid lines, the same three transcription initiation sites are found in both lines (Fig. 1). Moreover, as with the lymphoblastoid lines, start site utilization underwent a significant shift toward the upstream sites for expanded CGG alleles (87 repeats; Fig. 3; Table 2). The partitioning among the three sites in the astrocyte line with 87 CGG repeats is closer to the lymphoblastoid cell line with 60 CGG repeats than to the lymphoblastoid cell line with 82 CGG repeats, which may explain the absence of elevated FMR1 mRNA in the premutation (astrocyte) line. In this regard, the fractional utilization of site III is unchanged from the normal control, suggesting that the most upstream site may have a significant influence on translation. Taken together, these observations demonstrate that the number of CGG repeats, per se, is responsible for differences in transcription initiation, and that either the level or specificity of some additional factors are likely to play a role in FMR1 transcription initiation.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 3. Distribution of transcription start sites for normal (15 CGG), and premutation (87 CGG) primary cultured astrocytes; 100% is the total number of sequenced clones for each primary astrocyte cell culture. Bars are as represented in Figure 2.

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
In the current study, we have utilized 5'-RLM-RACE to demonstrate that transcription of the FMR1 gene is initiated at multiple transcription start sites for both neural (primary cultured astrocytes) and non-neuronal (lymphoblastoid) cells. We have also observed that the relative utilization of the three principal start sites is significantly altered for expanded-CGG alleles in the premutation range compared with normal alleles, indicating that the downstream CGG element has a direct influence on transcriptional initiation. The similar distributions of site utilization for cultured astrocytes and lymphoblastoid lines establish that the mechanism of start site selection for the FMR1 gene is not cell-type-specific. Furthermore, the elevated levels of total FMR1 mRNA in the premutation alleles, relative to the normal control, are consistent with an absolute increase in the utilization of sites II and III, not simply a shift away from site I. This latter observation suggests that the CGG element may be acting as a downstream enhancer for initiation at the more upstream sites (sites II and III).

No clones were identified that correspond precisely to the published transcription start site (6), although the principal start site in the control cell lines (site I) lies within 5 nt of the previously reported start site (6). It is possible that this residual difference is due to the lower precision of the primer extension method used previously, which was based on gel sizing. In addition, it is likely that the primer extension method lacked sufficient sensitivity to detect the minor transcription start sites (sites II and III) in a cell harboring normal alleles. An important advantage of 5'-RLM-RACE, relative to primer extension analysis as a means for accurate determination of the legitimate 5' ends of mRNAs, is that all non-capped RNAs are eliminated as candidates for RACE by calf intestinal protein (CIP) dephosphorylation (13,14).

The FMR1 promoter does not possess a typical TATA element, and deletion of the putative TATA-like sequence and an initiator-like (Inr) sequence (corresponding to site I only) does not dramatically reduce promoter activity (7). These observations support the idea that other transcription start sites as well as other important regulatory sequences are operating during transcriptional initiation from the FMR1 gene. In this regard, our observation of multiple start sites is not surprising, since many TATA-less promoters transcribed by RNA polymerase II initiate transcription at multiple start sites (17).

The FMR1 promoter region possesses three Inr sequences that correspond to sites I–III. The Inr-like sequences were identified by sequence similarity search using the Inr consensus sequence [YYAN(T/A)YY] (18,19) (Fig. 1). Inr sequences are usually located near transcription start sites and have been implicated in transcription initiation from TATA-less promoters (18,20). For the TATA-less promoters, binding of Inr-binding proteins to the Inr-elements on the promoter is thought to facilitate pol II complex formation either via interaction with TBP (TFIID) and/or other general and specific transcription factors, or by interacting with the CTD of RNA pol II (18). Among the several putative cis-regulatory elements within the promoter region of the FMR1 gene, USF1/USF2 and alpha-Pal/Nrf-1 appear to be major regulatory factors that are involved in activation of the FMR1 gene (7). Interestingly, USFs have been reported to be Inr-element-binding proteins (21,22), suggesting that these factors may be playing a role, perhaps via the Inr-like sequences associated with sites I–III, in the regulation of FMR1 transcription.

Although we have demonstrated that transcriptional initiation from the FMR1 gene is modulated by the downstream CGG repeat, the mechanism by which the CGG element influences start site selection is not known. One intriguing aspect of this coupling of CGG repeat size and start site utilization is that repeat expansion appears to direct the activation of the more upstream start sites. A precedent for such a modulator is the downstream element associated with the TATA-less promoter of the rat xanthine dehydrogenase/oxidase gene (XDH/XO), which contains four functional initiator sequences (Inr1, Inr2, Inr3 and Inr4) (20). In the absence of the downstream element, Inr 3 and Inr 4 are the major start sites; however, in the presence of the downstream element, the start site usage is shifted to Inr 1 and Inr 2, owing to YY-1 binding to the downstream element (23).

One possible mechanism by which the downstream CGG element could influence start site utilization would be through the interaction of a CGG binding protein with both the CGG element itself and components of the transcriptional regulatory machinery (e.g. USFs); such an interaction could be altered as a consequence of the increased length of the CGG repeat element. It is conceivable that the binding of additional CGG-BPs to the expanded repeat would lead to enhanced recruitment of pol II and increased production of FMR1 mRNA, as is observed among premutation carriers (9,11).

It is also possible that the expanded CGG repeat element exerts a direct effect, in cis, by modulating the local chromatin architecture (e.g. nucleosome positioning), thus altering accessibility of transcription factors to regions within the proximal FMR1 promoter. Previous studies have suggested that there may be a subtle effect of expanded CGG repeats on nucleosome affinity and/or positioning (24,25), and such positioning effects may influence start site selection.

In a more recent study of the effects of expanded CGG repeats on promoter activity, it was found that expanded CGG repeats had a repressive effect on HSV thymidine kinase activity upon injection of a reporter construct into Xenopus oocytes (26). Whereas the repressive effect was thought to be mediated by histone deacetylation, it is likely to be a specific phenomenon of the Xenopus system, or the use of a heterologous 5'-UTR, since such repressive effects are not observed for premutation alleles in patients (9,11) or in cultured cells that have been transfected with CGG repeats within the FMR1 5'-UTR context (27). However, the Xenopus study does raise the separate issue of how the CGG element may be contributing to the silencing process.

Finally, the use of post-mortem human brain tissue for the generation of cultured primary astrocytes with premutation CGG expansions represents an important advance in the study of fragile X syndrome. Using cultured astrocytes derived from brains with both normal and premutation alleles, we have shown that start site utilization in neural cells mirrors the pattern of initiation in peripheral tissues (lymphoblastoid cells). These results affirm that the mechanisms responsible for the differential distribution of these transcriptional start sites are functional in the brain and may thus represent a novel target for therapeutic intervention. These data also suggest that the harvesting of neural progenitor cells from these same tissues (16) may provide a preparation with which to investigate the effects of CGG expansions on both neuronal and astrocytic lineages. This latter capability should allow us to investigate the role of the CGG repeats per se, or the alternative start sites, in the pathogenesis of the newly-discovered fragile X-associated tremor/ataxia syndrome (FXTAS) (2830). These studies are currently underway.

In conclusion, this work extends our understanding of the mechanism of transcription initiation of the FMR1 gene. Our results indicate that the CGG repeat element in the FMR1 gene directly influences transcription initiation, raising the possibility that redistribution of the 5' ends of the FMR1 message could play a role in the reduced translation efficiency observed for premutation alleles.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Cell culture
Lymphoblastoid cell lines established by Epstein–Barr virus transformation were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco BRL), glutamine, and penicillin-streptomycin (Sigma) at 37°C in a humidified atmosphere of 5% CO2.

Primary astrocyte cell cultures were established in accord with UC Davis IRB-approved human subjects protocols from post-mortem normal and premutation human brain tissue following the Schwartz protocol (16). Primary astrocytes were maintained in DMEM medium supplemented with 15% fetal bovine serum (Gibco BRL), glutamine and penicillin–streptomycin (Sigma) at 37°C in a humidified atmosphere of 5% CO2. All lymphoblastoid cell lines and primary astrocytes cultures used in 5'-RLM-RACE studies are specified in Table 1.

PCR Southern blot hybridization analysis
DNA was extracted from cultured cells (Puregene DNA-isolation kit, Gentra) and analyzed by PCR with oligonucleotide primers specific for a portion of the FMR1 genomic DNA sequence that includes the CGG repeat region. The PCR primers used were c and f as described by Fu (31). PCR products were separated on a 6% polyacrylamide sequencing gel and transferred to a nylon membrane (Roche). Hybridization was performed with DIG labeled oligonucleotide probe (CGG)10 overnight in DIG Easy Hyb solution (Roche) at 42°C. Probe detection utilized anti-DIG antibody-alkaline phosphatase conjugate (Roche) with CDP-Star substrate (Roche). Further details of the PCR Southern blot hybridization method are reported by Tassone and Hagerman (32).

5'-RLM-RACE analysis of capped-RNA
Total RNA was isolated from lymphoblastoid cells and primary astrocytes using the Trizol method (Invitrogen). 5'-RLM-RACE was performed using GeneRacer kits (Invitrogen) according to the manufacturer's instructions. Three micrograms of total mRNA, or 0.5 µg of polyA(+) RNA, were used for each sample. Briefly, total mRNA, or polyA(+) RNA, was treated with calf intestinal phosphatase (CIP) to remove the 5' phosphates from any truncated (i.e. non-capped) mRNA. Dephosphorylated RNA was treated with tobacco acid pyrophosphatase (TAP) to remove the 5' cap from full-length mRNA, leaving a 5' phosphate. The GeneRacerTM RNA oligomer was then ligated to the 5' end of the mRNA using T7 RNA ligase. First-strand cDNA was produced with AMV-reverse-transcriptase using random hexamer primers. The regions corresponding to the legitimate 5' ends of the capped-RNA species were PCR amplified from cDNA templates using the GeneRacer 5' primer (5'-CGACTGGAGCACGAGGACACTGA-3') and an FMR1 gene-specific primer (5'-CTCGCCGTCGGCCCGCCGCC-3'). Nested PCR was performed with the GeneRacer 5' nested primer (5'-GGACACTGACATGGACTGAAGGAGTA-3') and the nested FMR1 gene specific primer (5'-CCTCCACCGGAAGTGAAACCGAAA-3'). The position of both FMR1-specific primers is indicated in Figure 1. The PCR products of the 5'-RLM-RACE RT-PCR reactions were cloned into pCR 4.1 vector (TA Cloning Kit, Invitrogen), and ligated products were transfected into One-Shot chemically competent cells (Invitrogen). Plasmids were purified using plasmid mini or midi kits (Promega), and were screened for insertions following EcoRI digestion. Positive clones for each transfection reaction were sequenced by means of an automated sequencer (ABI PRISM 310 Genetic Analyzer, Perkin Elmer) with T7 or T3 primers. Table 1 lists the number of clones that were sequenced for each lymphoblastoid line and primary astrocyte culture.

Preparation of polyA(+) RNA
PolyA(+) mRNA from lymphoblastoid cell lines with normal (21 or 29 CGG) and premutation (82 CGG) alleles was prepared using the PolyAPure mRNA Isolation System (Ambion), which is based on the elution of polyA mRNA from oligo (dT) cellulose columns, according to the manufacturer's protocol. ~5 µg of PolyA(+) mRNA were isolated from 106 cells for each lymphoblastoid cell line.

Statistical analysis
Chi-squared analyses were performed by global comparison of the site distributions (number of clones for each site) between pairs of alleles.


    ACKNOWLEDGEMENTS
 
The authors wish to thank Drs David Bentley and John Hershey for helpful discussions. We thank Lisa Becker for editorial assistance. This work was supported by a grant from the National Institute of Child Health and Development (P.J.H.; HD 40661), by the Boory and Cooper/Kraff/Fishman family funds (P.J.H.), by general laboratory support from the UC Davis MIND Institute and by Children's Hospital of Orange County Foundation for Children (P.H.S).


    FOOTNOTES
 
* To whom correspondence should be addressed at: Department of Biological Chemistry, University of California, Davis, School of Medicine, One Shields Avenue, Davis, CA 95616, USA. Tel: +1 5307547266; Fax: +1 5307547269; Email: pjhagerman{at}ucdavis.edu


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Pieretti, M., Zhang, F.P., Fu, Y.H., Warren, S.T., Oostra, B.A., Caskey, C.T. and Nelson, D.L. (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell, 66, 817–822.[CrossRef][ISI][Medline]

  2. Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.P. and Mandel, J.L. (1993) The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat. Genet., 4, 335–340.[CrossRef][ISI][Medline]

  3. Verheij, C., Bakker, C.E., de Graaff, E., Keulemans, J., Willemsen, R., Verkerk, A.J., Galjaard, H., Reuser, A.J., Hoogeveen, A.T. and Oostra, B.A. (1993) Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature, 363, 722–724.[CrossRef][Medline]

  4. Hagerman, P.J. (2002) Gene expression and molecular approaches to therapy. In Hagerman, R.J. and Hagerman, P.J. (eds), Fragile X Syndrome: Diagnosis, Treatment and Research, 3rd edn. The Johns Hopkins University Press, Baltimore, MD, pp. 465–494.

  5. Drouin, R., Angers, M., Dallaire, N., Rose, T.M., Khandjian, W. and Rousseau, F. (1997) Structural and functional characterization of the human FMR1 promoter reveals similarities with the hnRNP-A2 promoter region. Hum. Mol. Genet., 6, 2051–2060.[Abstract/Free Full Text]

  6. Hwu, W.L., Lee, Y.M., Lee, S.C. and Wang, T.R. (1993) In vitro DNA methylation inhibits FMR-1 promoter. Biochem. Biophys. Res. Commun., 193, 324–329.[CrossRef][ISI][Medline]

  7. Kumari, D. and Usdin, K. (2001) Interaction of the transcription factors USF1, USF2, and (alpha)-PAL/Nrf-1 with the FMR1 promoter. J. Biol. Chem., 276, 4357–4364.[Abstract/Free Full Text]

  8. Schwemmle, S., de Graaff, E., Deissler, H., Glaser, D., Wohrle, D., Kennerknecht, I., Just, W., Oostra, B.A., Dorfler, W., Vogel, W. et al. (1997) Characterization of FMR1 promoter elements by in vivo-footprinting analysis. Am. J. Hum. Genet., 60, 1354–1362.[ISI][Medline]

  9. Tassone, F., Hagerman, R.J., Chamberlain, W.D. and Hagerman, P.J. (2000) Transcription of the FMR1 gene in individuals with fragile X syndrome. Am. J. Med. Genet. (Semin. Med. Genet.), 97, 195–203.[CrossRef][ISI][Medline]

  10. Tassone, F., Hagerman, R.J., Taylor, A.K., Gane, L.W., Godfrey, T.E. and Hagerman, P.J. (2000) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in fragile X syndrome. Am. J. Hum. Genet., 66, 6–15.[CrossRef][ISI][Medline]

  11. Kenneson, A., Zhang, F., Hagedorn, C.H. and Warren, S.T. (2001) Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum. Mol. Genet., 10, 1449–1454.[Abstract/Free Full Text]

  12. Primerano, B., Tassone, F., Hagerman, R.J., Hagerman, P., Amaldi, F. and Bagni, C. (2002) Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA, 8, 1482–1488.[Abstract]

  13. Volloch, V., Schweitzer, B. and Rits, S. (1994) Ligation-mediated amplification of RNA from murine erythroid cells reveals a novel class of beta globin mRNA with an extended 5'-untranslated region. Nucl. Acids Res., 22, 2507–2511.[Abstract/Free Full Text]

  14. Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and Sugano, S. (1997) Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene, 200, 149–156.[CrossRef][ISI][Medline]

  15. Niikura, M., Dornadula, G., Zhang, H., Mukhtar, M., Lingxun, D., Khalili, K., Bagasra, O. and Pomerantz, R.J. (1996) Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell. Oncogene, 13, 313–322.[ISI][Medline]

  16. Schwartz, P.H., Bryant, P.J., Fuja, T.J., Su, H., O'Dowd, D.K. and Klassen, H. (2003) Isolation and characterization of neural progenitor cells from post-mortem human cortex. J. Neurosci. Res., 74, 838–851.[CrossRef][ISI][Medline]

  17. Kawai, Y., Asai, K., Miura, Y., Inoue, Y., Yamamoto, M., Moriyama, A., Yamamoto, N. and Kato, T. (2003) Structure and promoter activity of the human glia maturation factor-gamma gene: a TATA-less, GC-rich and bidirectional promoter. Biochim. Biophys. Acta, 1625, 246–252.[Medline]

  18. Weis, L. and Reinberg, D. (1992) Transcription by RNA polymerase II: initiator-directed formation of transcription-competent complexes. FASEB J., 6, 3300–3309.[Abstract]

  19. Javahery, R., Khachi, A., Lo, K., Zenzie-Gregory, B. and Smale, S.T. (1994) DNA sequence requirements for transcriptional initiator activity in mammalian cells. Mol. Cell. Biol., 14, 116–127.[Abstract/Free Full Text]

  20. Chow, C.W., Clark, M.P., Rinaldo, J.E. and Chalkley, R. (1995) Multiple initiators and C/EBP binding sites are involved in transcription from the TATA-less rat XDH/XO basal promoter. Nucl. Acids Res., 23, 3132–3140.[Abstract/Free Full Text]

  21. Roy, A.L., Meisterernst, M., Pognonec, P. and Roeder, R.G. (1991) Cooperative interaction of an initiator-binding transcription initiation factor and the helix–loop–helix activator USF. Nature, 354, 245–248.[CrossRef][Medline]

  22. Du, H., Roy, A.L. and Roeder, R.G. (1993) Human transcription factor USF stimulates transcription through the initiator elements of the HIV-1 and the Ad-ML promoters. EMBO J., 12, 501–511.[ISI][Medline]

  23. Clark, M.P., Chow, C.W., Rinaldo, J.E. and Chalkley, R. (1998) Correct usage of multiple transcription initiation sites and C/EBP-dependent transcription activation of the rat XDH/XO TATA-less promoter requires downstream elements located in the coding region of the gene. Nucl. Acids Res., 26, 1801–1806.[Abstract/Free Full Text]

  24. Wang, Y.H., Gellibolian, R., Shimizu, M., Wells, R.D. and Griffith, J. (1996) Long CCG triplet repeat blocks exclude nucleosomes: a possible mechanism for the nature of fragile sites in chromosomes. J. Mol. Biol., 263, 511–516.[CrossRef][ISI][Medline]

  25. Godde, J.S., Kass, S.U., Hirst, M.C. and Wolffe, A.P. (1996) Nucleosome assembly on methylated CGG triplet repeats in the fragile X mental retardation gene 1 promoter. J. Biol. Chem., 271, 24325–24328.[Abstract/Free Full Text]

  26. Chandler, S., Kansagra, P. and Hirst, M. (2003) Fragile X (CGG)n repeats induce a transcriptional repression in cis upon a linked promoter: evidence for a chromatin mediated effect. BMC Mol. Biol., 4, 3.[CrossRef][Medline]

  27. Chen, L.S., Tassone, F., Sahota, P. and Hagerman, P.J. (2003) The (CGG)n repeat element within the 5' untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum. Mol. Genet., 12, 3067–3074.[Abstract/Free Full Text]

  28. Hagerman, R.J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., Grigsby, J., Gage, B. and Hagerman, P.J. (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology, 57, 127–130.[Abstract/Free Full Text]

  29. Greco, C.M., Hagerman, R.J., Tassone, F., Chudley, A.E., Del Bigio, M.R., Jacquemont, S., Leehey, M. and Hagerman, P.J. (2002) Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain, 125, 1760–1771.[Abstract/Free Full Text]

  30. Jacquemont, S., Hagerman, R.J., Leehey, M., Grigsby, J., Zhang, L., Brunberg, J.A., Greco, C., Des Portes, V., Jardini, T., Levine, R. et al. (2003) Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am. J. Hum. Genet., 72, 869–878.[CrossRef][ISI][Medline]

  31. Fu, Y.H., Kuhl, D.P., Pizzuti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkerk, A.J., Holden, J.J., Fenwick, R.G., Jr., Warren, S.T. et al. (1991) Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell, 67, 1047–1058.[CrossRef][ISI][Medline]

  32. Tassone, F. and Hagerman, P.J. (2003) Expression of the FMR1 gene. Cytogenet. Genome Res., 100, 124–128.[CrossRef][ISI][Medline]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Genome ResHome page
K. Usdin
The biological effects of simple tandem repeats: Lessons from the repeat expansion diseases
Genome Res., July 1, 2008; 18(7): 1011 - 1019.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
P. D. Ladd, L. E. Smith, N. A. Rabaia, J. M. Moore, S. A. Georges, R. S. Hansen, R. J. Hagerman, F. Tassone, S. J. Tapscott, and G. N. Filippova
An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals
Hum. Mol. Genet., December 15, 2007; 16(24): 3174 - 3187.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
S. Khateb, P. Weisman-Shomer, I. Hershco-Shani, A. L. Ludwig, and M. Fry
The tetraplex (CGG)n destabilizing proteins hnRNP A2 and CBF-A enhance the in vivo translation of fragile X premutation mRNA
Nucleic Acids Res., September 27, 2007; 35(17): 5775 - 5788.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
F. Tassone, A. Beilina, C. Carosi, S. Albertosi, C. Bagni, L. Li, K. Glover, D. Bentley, and P. J. Hagerman
Elevated FMR1 mRNA in premutation carriers is due to increased transcription
RNA, April 1, 2007; 13(4): 555 - 562.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
K. T. Smith, R. D. Nicholls, and D. Reines
The gene encoding the fragile X RNA-binding protein is controlled by nuclear respiratory factor 2 and the CREB family of transcription factors
Nucleic Acids Res., February 25, 2006; 34(4): 1205 - 1215.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. M. Greco, R. F. Berman, R. M. Martin, F. Tassone, P. H. Schwartz, A. Chang, B. D. Trapp, C. Iwahashi, J. Brunberg, J. Grigsby, et al.
Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS)
Brain, January 1, 2006; 129(1): 243 - 255.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. J. Mulvihill, K. N. Edamura, K. A. Hagerman, C. E. Pearson, and Y.-H. Wang
Effect of CAT or AGG Interruptions and CpG Methylation on Nucleosome Assembly upon Trinucleotide Repeats on Spinocerebellar Ataxia, Type 1 and Fragile X Syndrome
J. Biol. Chem., February 11, 2005; 280(6): 4498 - 4503.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. Napierala, D. Michalowski, M. de Mezer, and W. J. Krzyzosiak
Facile FMR1 mRNA structure regulation by interruptions in CGG repeats
Nucleic Acids Res., January 19, 2005; 33(2): 451 - 463.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Dere, M. Napierala, L. P. W. Ranum, and R. D. Wells
Hairpin Structure-forming Propensity of the (CCTG{middle dot}CAGG) Tetranucleotide Repeats Contributes to the Genetic Instability Associated with Myotonic Dystrophy Type 2
J. Biol. Chem., October 1, 2004; 279(40): 41715 - 41726.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
K. T. Smith, B. Coffee, and D. Reines
Occupancy and synergistic activation of the FMR1 promoter by Nrf-1 and Sp1 in vivo
Hum. Mol. Genet., August 1, 2004; 13(15): 1611 - 1621.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/5/543    most recent
ddh053v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Beilina, A.
Right arrow Articles by Hagerman, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beilina, A.
Right arrow Articles by Hagerman, P. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?